Dr. Agarwal's Health Care Limited announces an acquisition

The exact share exchange ratio is not stated in the cited material, so the post-merger number of Dr. Agarwal’s Health Care shares cannot be calculated reliably from the evidence available. The scheme had received shareholder approval on 2 July 2026, but remained subject to NCLT sanction; an NCLT hearing was scheduled for 19 August 2026. ^[1]

Capital-base comparison

Mechanically, assuming the scheme issues shares only to Eye Hospital shareholders:

Post-merger equity share capital = Health Care’s existing share capital + new shares issued to Eye Hospital shareholders × Rs 1 face value.

The new-share component requires two missing inputs: the approved exchange ratio and the number of Eye Hospital shares outstanding immediately before the merger. The company’s investor-presentation and amalgamation documents are listed, but their substantive ratio and capital-structure details are not reproduced in the cited source. ^[4]

Accordingly, the supported conclusion is that the merger would enlarge Health Care’s equity base through shares issued to Eye Hospital shareholders, but the magnitude of dilution and the resulting post-merger capital cannot be stated without those scheme terms.

The amalgamation should simplify the balance sheet, but it does not by itself reduce external debt. Inter-company loans, receivables/payables and any qualifying cross-holdings would be canceled on consolidation or merger; third-party borrowings of Dr. Agarwal’s Eye Hospital Limited would transfer to Dr. Agarwal’s Health Care Limited and remain debt obligations.

The scheme identifies Eye Hospital as the transferor and Health Care as the transferee; it was still subject to NCLT sanction, with a hearing scheduled for 19 August 2026. ^[1] Therefore, the latest audited FY26 numbers should not yet be interpreted as a post-amalgamation balance sheet.

Effect on debt and inter-company balances

The important distinction is between gross debt elimination and inter-company balance elimination:

• If Eye Hospital owed money to Health Care, or vice versa, canceling that balance removes both the asset and liability from the combined entity. It does not reduce the group’s obligations to banks or other external lenders.
• If one entity held shares in the other, that internal investment would not represent an asset of the merged economic group after completion. Its elimination could affect standalone balance sheets, share capital, reserves or goodwill, but it should not be treated as operating deleveraging.
• The consolidated debt ratios already present the group’s external leverage after normal consolidation eliminations. The FY26 consolidated debt/equity ratio was 0.08x and interest coverage was 7.88x. ^{[10] [11]}

The company’s investor page confirms that FY26 audited consolidated and standalone results, along with a supplementary accounting statement, were published. ^[4] However, the specific audited note quantifying loans, receivables, payables, cross-holdings and merger-adjustment entries is not included in the cited material. Accordingly, the defensible conclusion is balance-sheet simplification and removal of internal claims, but no demonstrated reduction in external consolidated debt until the post-effective-date financial statements disclose it.

Appointed Date: The merger is deemed effective from the opening of business on 1 April 2026. This is distinct from the Operative/Effective Date, which will be the first day of the calendar month after all conditions under Clause 24 of the scheme are completed. ^[12]

Post-sanction actions still identified:

• The certified copy of the NCLT order was still awaited as of the company’s 5 October 2026 filing. ^[12]
• The company must communicate to the stock exchanges when the scheme becomes effective.
• It must subsequently disclose the record date, the share allotment under the share-exchange ratio, and other implementation developments. ^[12]

Form INC-28: The cited company disclosure does not specifically state whether Form INC-28 has been filed or remains outstanding, nor does it provide a complete checklist of Registrar of Companies filings. Therefore, INC-28 should not be treated as confirmed pending based solely on this update.

The accounting implication is that the Eye Hospital business should be incorporated into the transferee’s financial reporting only after the scheme’s operative conditions and implementation formalities are completed; the 1 April 2026 Appointed Date determines the scheme’s effective reference date but does not, by itself, establish that all post-sanction filings and share-allotment steps are complete.